Asia-Pacific
18 February 2026 The science and technology conglomerate’s big diagnostics bet comes with monitoring technology, an AI-powered product pipeline, and a litigation history that has kept Silicon Valley’s biggest player on the back foot.
17 February 2026
23 September 2025
3 October 2023
23 February 2023
Latest Features
Africa
The global pandemic has increased collaboration and a new wave of disputes is likely. Arbitration is well placed to help, argue Kate Davies McGill, Gaela Gehring Flores and Paul Keller of Allen & Overy
Africa
There may be a path through the CRISPR patent jungle, but there are many obstacles still in the way, say European academics Timo Minssen, Esther van Zimmeren and Jakob Wested.
Asia-Pacific
Yoshinori Ohsumi was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the business and innovation section, as LSIPR reports.
Africa
With specialist IP providers offering post-M&A services at lower cost than traditional law firms, have clients been overspending in the past? Melissa Pillote on behalf of Dennemeyer reports.
Africa
‘Technological intelligence’ is very important for extracting maximum value from technology transfer deals, and life sciences companies should use it to their advantage, says Montserrat González-Álvarez of Leyva, Montenegro, Trigueros Abogados.
Africa
In a world where research projects are increasingly carried out by several parties in different countries, companies should consider a number of IP-related issues before embarking on multiterritorial collaborations, say Oliver Laing and Tony Proctor of Potter Clarkson.
Africa
There is some debate about whether the ‘patent cliff’ or the need to innovate is driving M&A activity in the pharmaceutical industry, where billions of dollars have been spent in the past few years, as LSIPR finds out.
Asia-Pacific
In Australia, laws governing the patentability of inventions directed to gene-based technology, including isolated naturally occurring and artificial gene sequences, are contentious. Unlike the US situation, the law on patentability of inventions involving “principles of nature” in Australia has yet to be considered judicially, but that is about to change, says Grant Shoebridge of Shelston IP.
More News
30 November 2020 The Federal Court of Australia has granted Pfizer subsidiary Wyeth’s bid for an injunction against Merck Sharp Dohme in a dispute over vaccine patents.
15 October 2020 In a mixed decision for Merck Sharp Dohme, the Federal Court of Australia has concluded that the pharmaceutical company is infringing one patent owned by Wyeth, but that two other Wyeth patents are invalid.
25 August 2020 Law firm Spruson & Ferguson has appointed four new principals across the firm as part of its 2020 promotions. The appointments have been made in the firm’s Hong Kong, Singapore, Sydney and Melbourne offices.
3 August 2020 A former researcher at the research institute of the Nationwide Children’s Hospital in Ohio has pleaded guilty to conspiring to steal scientific trade secrets to sell in China.
6 July 2020 The Federal Court of Australia has upheld a patent victory for Indian generic manufacturer Sun Pharma over Mylan in a dispute over cholesterol drug fenofibrate.
15 June 2020 Swiss healthcare company Roche has partnered with Chinese biotech Innovent Biologics to develop cell therapies and bispecific antibodies.
29 May 2020 The World Health Organization has launched a COVID-19 technology pool, with 37 countries and multiple international partners and institutions rallying together to support the initiative.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox